FIG. 1





FIG. 2


Unstained
Control
ETV2-OE
CD235a
SSC-A
CD34
CD31
Gated on GFP+
60.0%
27.8%
64.0%
61.2%
CD235a-CD34+CD31+ (%)
0
20
40
60
80
Control
ETV2-OE
*
*P<0.05



Gated on GFP+
Unstained
Control
ETV2-OE
CD34+
SSC-A
18.6%
49.3%
CD34+ (%)
80
60
40
20
0
*
Control
ETV2-OE
*P<0.05

FIG. 3




Unstained
BM-HSCs
iPSC-HSCs
(Piezo1 activation)
0.02%
10.9%
CD34
CD7

FIG. 4A

FIG. 4B





Unstained
BM-HSCs
iPSC-HSCs
(Piezo1 activation)
28.7%
21.6%
CD3
CD69

FIG. 5A

FIG. 5B





FIG. 6


IFNγ expression level relative to GAPDH
3
2
1
0
*
iPSC-HSCs
iPSC-HSCs (Piezo1 activation)